<p><img src="https://imageproxy.pbkrs.com/https://www.pharmexec.com/_next/image/query-cT03NSZ1cmw9aHR0cHM6Ly9jZG4uc2FuaXR5LmlvL2ltYWdlcy8wdnY4bW9jNi9waGFybWV4ZWMvNzM2ZWQyOTEwMjU0NzAxZjcwOTg5ZDMxNDY1NTkyNzRlNGIwZTRhZS0xMjgweDcyMC5wbmc_Zml0PWNyb3AmYXV0bz1mb3JtYXQmdz0zODQw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmexec.com/_next/image/query-cT03NSZ1cmw9aHR0cHM6Ly9jZG4uc2FuaXR5LmlvL2ltYWdlcy8wdnY4bW9jNi9waGFybWV4ZWMvNzM2ZWQyOTEwMjU0NzAxZjcwOTg5ZDMxNDY1NTkyNzRlNGIwZTRhZS0xMjgweDcyMC5wbmc_Zml0PWNyb3AmYXV0bz1mb3JtYXQmdz0zODQw"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.sanity.io/images/0vv8moc6/pharmexec/736ed2910254701f70989d3146559274e4b0e4ae-1280x720.png/query-YXV0bz1mb3JtYXQmZml0PWNyb3A?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.sanity.io/images/0vv8moc6/pharmexec/736ed2910254701f70989d3146559274e4b0e4ae-1280x720.png/query-YXV0bz1mb3JtYXQmZml0PWNyb3A"/></p>
<p>诺和诺德正在采取进一步措施，以确保患者能够获得其受欢迎的 GLP-1 药物 Wegovy。</p>
<p>本月早些时候，该公司宣布了一项新服务，旨在为没有保险或其保险计划不涵盖减肥药物的患者提供药物获取途径。</p>
<p>NovoCare 药房是一项直接面向患者的服务，提供不同剂量的 Wegovy。患者可以以 499 美元的现金支付购买一个月的药物供应。最初，这一降价仅通过诺和诺德的 DTC 药房提供。</p>
<p>现在，该公司正在扩大这一折扣，使其也适用于在当地药房现金支付的患者。诺和诺德称该项目为 Beyond NovoCare Pharmacy。根据公司的说法，这是公司确保患者能够获得真正药物的举措的一部分，患者不必求助于购买潜在危险的仿制药。</p>
<p>在宣布扩展的新闻稿中，诺和诺德美国运营和全球业务发展副总裁 Dave Moore 说：“在诺和诺德，我们致力于开发创新药物，并将继续优先考虑使其对我们服务的社区可及和负担得起。随着我们 Wegovy® 节省计划的发展，我们继续提供选项，使生活在肥胖中的人们更容易追求他们的体重管理和健康目标。”</p>
<p>诺和诺德首次在 2025 年 3 月宣布了 NovoCare 药房。这是行业中一个更大趋势的一部分，制药公司正在扩大其 DTC 产品，以试图降低患者的成本。通过这些渠道提供药物，制药公司能够通过避免某些障碍（如 PBMS）来降低成本。它还为他们提供了直接向可能没有保险覆盖的患者提供折扣的机会。</p>
<p>在当时发布的新闻稿中，Moore 说：“诺和诺德继续推进为患者提供的解决方案，以改善我们药物的可负担性和可及性，无论他们是否有保险。如今，美国有超过 5500 万人专门覆盖减肥药物，90% 的 Wegovy® 患者有保险每月支付 0 到 25 美元。通过 NovoCare® 药房，患者和开处方者都有另一个选项，可以以降低的成本方便地获得所有剂量的真正 FDA 批准的 Wegovy®。”</p>
<p>Wegovy 是一种因其减肥效果而备受欢迎的药物。在过去的几年中，诺和诺德在满足美国对该药物的需求方面遇到了困难，并不得不暂时限制新的处方。虽然这一限制在去年被解除，但美国的药物供应仍被认为是低的。然而，FDA 最近宣布短缺问题已正式结束。</p>
<p>在 2025 年 2 月的一份新闻稿中，Moore 说：“我们很高兴 FDA 宣布唯一真正的、 FDA 批准的 semaglutide 药物的供应问题已解决，确认诺和诺德正在满足或超过当前和预计的全国需求。没有人应该因为错误信息而妥协他们的健康，去寻找假冒或不合法的仿制药，这对患者构成重大安全风险。患者安全始终是我们的首要任务，按照我们改善生活和健康的宗旨，我们将继续合作、教育和倡导，为那些需要和依赖我们药物的人提供更广泛、可负担的获取途径。”</p>
<h2>来源</h2>
<ol>
<li>诺和诺德通过 Wegovy® 节省计划将 Wegovy® 每月 499 美元的优惠扩展到更多现金支付患者。_诺和诺德公司_2025 年 3 月 24 日。 https://www.prnewswire.com/news-releases/novo-nordisk-expands-wegovy-499-per-month-offering-to-additional-cash-paying-patients-via-the-wegovy-savings-offer-302408528.html</li>
<li>诺和诺德推出 NovoCare® 药房，将所有 FDA 批准的 Wegovy®（semaglutide）价格降低至每月 499 美元，并为现金支付患者提供便捷的家庭配送。_诺和诺德公司_2025 年 3 月 5 日。访问日期：2025 年 3 月 24 日。 https://www.prnewswire.com/news-releases/novo-nordisk-introduces-novocare-pharmacy-lowering-cost-of-all-doses-of-fda-approved-wegovy-semaglutide-to-499-per-month-and-offering-easy-home-delivery-for-cash-paying-patients-302392874.html</li>
<li>FDA 宣布 Wegovy® 和 Ozempic® 短缺问题已结束，诺和诺德完全满足或超过所有剂量的全国需求。_诺和诺德公司_2025 年 2 月 21 日。访问日期：2025 年 3 月 24 日。 https://www.prnewswire.com/news-releases/fda-declares-wegovy-and-ozempic-shortage-is-over-and-that-novo-nordisk-is-fully-meeting-or-exceeding-nationwide-demand-for-all-doses-302382370.html</li>
</ol>

诺和诺德公司

<p>诺和诺德公司正在通过推出一项名为 Beyond NovoCare Pharmacy 的新服务来扩大其 GLP-1 药物 Wegovy 的可及性。该举措允许现金支付的患者在当地药房以每月 499 美元的优惠价格购买 Wegovy，此外还提供现有的直接面向患者的服务。该公司旨在确保患者的安全和药物的可负担性，因为在美国有超过 5500 万人享有体重管理药物的保险覆盖。美国食品药品监督管理局（FDA）最近确认 Wegovy 的供应短缺问题已得到解决，使诺和诺德能够满足需求</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmexec.com/_next/image/query-cT03NSZ1cmw9aHR0cHM6Ly9jZG4uc2FuaXR5LmlvL2ltYWdlcy8wdnY4bW9jNi9waGFybWV4ZWMvNzM2ZWQyOTEwMjU0NzAxZjcwOTg5ZDMxNDY1NTkyNzRlNGIwZTRhZS0xMjgweDcyMC5wbmc_Zml0PWNyb3AmYXV0bz1mb3JtYXQmdz0zODQw" alt="" original-src="https://www.pharmexec.com/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpharmexec%2F736ed2910254701f70989d3146559274e4b0e4ae-1280x720.png%3Ffit%3Dcrop%26auto%3Dformat&amp;w=3840&amp;q=75"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.sanity.io/images/0vv8moc6/pharmexec/736ed2910254701f70989d3146559274e4b0e4ae-1280x720.png/query-YXV0bz1mb3JtYXQmZml0PWNyb3A" alt="" original-src="https://cdn.sanity.io/images/0vv8moc6/pharmexec/736ed2910254701f70989d3146559274e4b0e4ae-1280x720.png?fit=crop&amp;auto=format"/></p>
<p>Novo Nordisk is taking further steps to ensure patient access to its popular GLP-1 medication Wegovy.1</p>
<div class="lb-trans"><p>诺和诺德正在采取进一步措施，以确保患者能够获得其受欢迎的 GLP-1 药物 Wegovy。</p>
</div><p>Earlier this month, the company announced a new service aimed at providers patients access to the medication if they didn’t have insurance or their insurance plan didn’t cover weight-loss medications.</p>
<div class="lb-trans"><p>本月早些时候，该公司宣布了一项新服务，旨在为没有保险或其保险计划不涵盖减肥药物的患者提供药物获取途径。</p>
</div><p>NovoCare Pharmacy is a direct-to-patient service that offers various dosages of Wegovy. Patients can purchase a month’s supply for a $499 cash payment. Originally, this reduced price was only available through Novo Nordisk’s DTC pharmacy.</p>
<div class="lb-trans"><p>NovoCare 药房是一项直接面向患者的服务，提供不同剂量的 Wegovy。患者可以以 499 美元的现金支付购买一个月的药物供应。最初，这一降价仅通过诺和诺德的 DTC 药房提供。</p>
</div><p>Now, the company is expanding that discount to make it available for cash-paying patients at their local pharmacies as well. Novo Nordisk calls the program Beyond NovoCare Pharmacy. According to the company, this is part of an initiative at the company to ensure that patients are able to access the genuine medication and don’t have to resort to purchasing potentially dangerous knockoffs.</p>
<div class="lb-trans"><p>现在，该公司正在扩大这一折扣，使其也适用于在当地药房现金支付的患者。诺和诺德称该项目为 Beyond NovoCare Pharmacy。根据公司的说法，这是公司确保患者能够获得真正药物的举措的一部分，患者不必求助于购买潜在危险的仿制药。</p>
</div><p>In a press release announcing the expansion, Novo Nordisk executive vice or US operations and global business development Dave Moore said, “At Novo Nordisk, we are committed to developing innovative medicines and will continue to prioritize making them accessible to and affordable for the communities we serve. With the evolution of our Wegovy® savings program, we continue to deliver options that empower people living with obesity to more easily pursue their weight management and health goals.&#34;</p>
<div class="lb-trans"><p>在宣布扩展的新闻稿中，诺和诺德美国运营和全球业务发展副总裁 Dave Moore 说：“在诺和诺德，我们致力于开发创新药物，并将继续优先考虑使其对我们服务的社区可及和负担得起。随着我们 Wegovy® 节省计划的发展，我们继续提供选项，使生活在肥胖中的人们更容易追求他们的体重管理和健康目标。”</p>
</div><p>Novo Nordisk first announced the NovoCare Pharmacy in March, 2025.2 This is part of a larger trend in the industry where pharma companies are expanding their DTC offerings in attempts to reduce costs for patients. By offering medications through these channels, pharma companies are able to reduce costs by avoiding certain hurdles like PBMS. It also provides them the opportunity to offer discounts directly to patients who may not have the medications covered by their insurance policies.</p>
<div class="lb-trans"><p>诺和诺德首次在 2025 年 3 月宣布了 NovoCare 药房。这是行业中一个更大趋势的一部分，制药公司正在扩大其 DTC 产品，以试图降低患者的成本。通过这些渠道提供药物，制药公司能够通过避免某些障碍（如 PBMS）来降低成本。它还为他们提供了直接向可能没有保险覆盖的患者提供折扣的机会。</p>
</div><p>In a press release issued at the time, Moore said, “Novo Nordisk continues to advance solutions for patients that improve affordability and access to our medicines, whether they have insurance or not. Today, over 55 million people in the U.S. have coverage specifically for weight management medicines, and 90% of Wegovy® patients with coverage pay $0 to $25 a month for Wegovy®. With NovoCare® Pharmacy, patients and prescribers alike have another option that provides convenient access to all doses of real, FDA-approved Wegovy® at a reduced cost in our high-quality pen.&#34;</p>
<div class="lb-trans"><p>在当时发布的新闻稿中，Moore 说：“诺和诺德继续推进为患者提供的解决方案，以改善我们药物的可负担性和可及性，无论他们是否有保险。如今，美国有超过 5500 万人专门覆盖减肥药物，90% 的 Wegovy® 患者有保险每月支付 0 到 25 美元。通过 NovoCare® 药房，患者和开处方者都有另一个选项，可以以降低的成本方便地获得所有剂量的真正 FDA 批准的 Wegovy®。”</p>
</div><p>Wegovy is a highly popular medication due to its weight-loss benefits. In previous years, Novo Nordisk struggled to meet the demand for the drug in the United States and had to temporarily limit new prescriptions for a time. While that limitation was lifted last year, the supply of the drug in the US was still considered to be low. However, FDA recently declared that the shortage was officially over.3</p>
<div class="lb-trans"><p>Wegovy 是一种因其减肥效果而备受欢迎的药物。在过去的几年中，诺和诺德在满足美国对该药物的需求方面遇到了困难，并不得不暂时限制新的处方。虽然这一限制在去年被解除，但美国的药物供应仍被认为是低的。然而，FDA 最近宣布短缺问题已正式结束。</p>
</div><p>In a press release from February, 2025, Moore said, “We are pleased the FDA has declared that supply of the only real, FDA-approved semaglutide medicines is resolved, affirming that Novo Nordisk is meeting or exceeding current and projected nationwide demand. No one should have to compromise their health due to misinformation and reach for fake or illegitimate knockoff drugs that pose significant safety risks to patients. Patient safety remains our top priority and, in line with our purpose to improve lives and health, we continue to partner, educate, and advocate for expanded, affordable access to our medicines for those who need and rely on them.&#34;</p>
<div class="lb-trans"><p>在 2025 年 2 月的一份新闻稿中，Moore 说：“我们很高兴 FDA 宣布唯一真正的、 FDA 批准的 semaglutide 药物的供应问题已解决，确认诺和诺德正在满足或超过当前和预计的全国需求。没有人应该因为错误信息而妥协他们的健康，去寻找假冒或不合法的仿制药，这对患者构成重大安全风险。患者安全始终是我们的首要任务，按照我们改善生活和健康的宗旨，我们将继续合作、教育和倡导，为那些需要和依赖我们药物的人提供更广泛、可负担的获取途径。”</p>
</div><h2>SOURCES</h2>
<div class="lb-trans"><h2>来源</h2>
</div><ol>
<li>Novo Nordisk Expands Wegovy® $499-Per-Month Offering to Additional Cash-Paying Patients via the Wegovy® Savings Offer. <em>Novo Nordisk Inc</em>. March 24, 2025. https://www.prnewswire.com/news-releases/novo-nordisk-expands-wegovy-499-per-month-offering-to-additional-cash-paying-patients-via-the-wegovy-savings-offer-302408528.html</li>
<li>Novo Nordisk Introduces NovoCare® Pharmacy, Lowering Cost of All Doses of FDA-Approved Wegovy® (semaglutide) to $499 Per Month and Offering Easy Home Delivery for Cash-Paying Patients. <em>Novo Nordisk Inc</em>. March 5, 2025. Accessed March 24, 2025. https://www.prnewswire.com/news-releases/novo-nordisk-introduces-novocare-pharmacy-lowering-cost-of-all-doses-of-fda-approved-wegovy-semaglutide-to-499-per-month-and-offering-easy-home-delivery-for-cash-paying-patients-302392874.html</li>
<li>FDA Declares Wegovy® and Ozempic® Shortage is Over and That Novo Nordisk is Fully Meeting or Exceeding Nationwide Demand for All Doses. <em>Novo Nordisk Inc</em>. February 21, 2025. Accessed March 24, 2025. https://www.prnewswire.com/news-releases/fda-declares-wegovy-and-ozempic-shortage-is-over-and-that-novo-nordisk-is-fully-meeting-or-exceeding-nationwide-demand-for-all-doses-302382370.html</li>
</ol>
<div class="lb-trans"><ol>
<li>诺和诺德通过 Wegovy® 节省计划将 Wegovy® 每月 499 美元的优惠扩展到更多现金支付患者。_诺和诺德公司_2025 年 3 月 24 日。 https://www.prnewswire.com/news-releases/novo-nordisk-expands-wegovy-499-per-month-offering-to-additional-cash-paying-patients-via-the-wegovy-savings-offer-302408528.html</li>
<li>诺和诺德推出 NovoCare® 药房，将所有 FDA 批准的 Wegovy®（semaglutide）价格降低至每月 499 美元，并为现金支付患者提供便捷的家庭配送。_诺和诺德公司_2025 年 3 月 5 日。访问日期：2025 年 3 月 24 日。 https://www.prnewswire.com/news-releases/novo-nordisk-introduces-novocare-pharmacy-lowering-cost-of-all-doses-of-fda-approved-wegovy-semaglutide-to-499-per-month-and-offering-easy-home-delivery-for-cash-paying-patients-302392874.html</li>
<li>FDA 宣布 Wegovy® 和 Ozempic® 短缺问题已结束，诺和诺德完全满足或超过所有剂量的全国需求。_诺和诺德公司_2025 年 2 月 21 日。访问日期：2025 年 3 月 24 日。 https://www.prnewswire.com/news-releases/fda-declares-wegovy-and-ozempic-shortage-is-over-and-that-novo-nordisk-is-fully-meeting-or-exceeding-nationwide-demand-for-all-doses-302382370.html</li>
</ol>
</div>

诺和诺德公司扩大了 Wegovy 的折扣获取范围